臨床泌尿器科78巻7号

2024年06月発行

特集 キャッチアップ精巣腫瘍―今，知っておくべき進歩 〈オーバービュー〉

精巣腫瘍の薬物療法（全身化学療法）の進歩

著者： 原勲¹

所属機関： ¹和歌山県立医科大学 泌尿器科

ページ範囲：P.452 - P.461

▶ポイント

・転移性精巣腫瘍は抗がん薬に対する感受性がきわめて良好であり，標準治療とされるBEP療法を適切に施行することにより70〜80％の症例で完治が期待できる．

・ブレオマイシンの肺毒性を避けたい症例ではBEP療法3コースの代替としてはEP療法4コースが，BEP療法4コースの代替としてはVIP療法4コースが推奨される．

・救済化学療法としてパクリタキセルを含んだTIP療法が施行されている．

・大量化学療法に関して導入化学療法としての意義は限定的である．救済化学療法としてTIP療法とのランダム化比較試験が現在進行中である．

参考文献

1） Einhorn LH, et al : Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87 : 293-298, 1977

2） Williams SD, et al : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 : 1435-1440, 1987

3） International Germ Cell Consensus Classification : a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15 : 594-603, 1997

4） de Wit R, et al : Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma : a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78 : 828-832, 1998

5） Hinton S, et al : Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors : final analysis of an intergroup trial. Cancer 97 : 1869-1875, 2003

6） Fizazi K, et al : Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours （GETUG 13） : a phase 3, multicentre, randomised trial. Lancet Oncol 15 : 1442-1450, 2014

7） Daugaard G, et al : A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide （VIP） plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal （EORTC 30974）. Ann Oncol 22 : 1054-1061, 2011

8） Motzer RJ, et al : Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25 : 247-256, 2007

9） de Wit R, et al : Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin （BEP） to standard BEP in intermediate-prognosis germ-cell cancer : intergroup study EORTC 30983. J Clin Oncol 30 : 792-799, 2012

10） Cafferty FH, et al : Long-term outcomes with intensive induction chemotherapy （carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin） and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours : A randomised phase II trial （ISRCTN53643604）. Eur J Cancer 127 : 139-149, 2020

11） O'Sullivan JM, et al : Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14 : 91-96, 2003

12） Loehrer PJ Sr, et al : Importance of bleomycin in favorable-prognosis disseminated germ cell tumors : an Eastern Cooperative Oncology Group trial. J Clin Oncol 13 : 470-476, 1995

13） Cary C, et al : Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection : A Comparison of BEP × 3 vs. EP × 4 and Treating Institution. Clin Genitourin Cancer 16 : e307-e313, 2018

14） Culine S, et al : Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors : a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers （GETUG T93BP）. Ann Oncol 18 : 917-924, 2007

15） Zon RT, et al : Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 16 : 1294-1297, 1998

16） Lorch A, et al : Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors : evidence from a large international database. J Clin Oncol 29 : 2178-2184, 2011

17） McCaffrey JA, et al : Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors : response and survival. J Clin Oncol 15 : 2559-2563, 1997

18） Kondagunta GV, et al : Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23 : 6549-6555, 2005

19） Kurobe M, et al : Paclitaxel, ifosfamide, and cisplatin （TIP） as salvage and consolidation chemotherapy for advanced germ cell tumor. J Cancer Res Clin Oncol 141 : 127-133, 2015

20） Mead GM, et al : A phase II trial of TIP （paclitaxel, ifosfamide and cisplatin） given as second-line （post-BEP） salvage chemotherapy for patients with metastatic germ cell cancer : a medical research council trial. Br J Cancer 93 : 178-184, 2005

21） Narayan V, et al : Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. Clin Genitourin Cancer 14 : 524-529, 2016

22） Park S, et al : Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin （TIP） in relapsed or cisplatin-refractory germ cell tumors. Onkologie 34 : 416-420, 2011

23） Pico JL, et al : A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16 : 1152-1159, 2005

24） Lorch A, et al : Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors : a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 25 : 2778-2784, 2007

25） Adra N, et al : High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors : The Indiana University Experience. J Clin Oncol 35 : 1096-1102, 2017

26） McHugh DJ, et al : Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors. Adv Urol 2018 : 7272541, 2018

27） Pectasides D, et al : Gemcitabine and oxaliplatin （GEMOX） in patients with cisplatin-refractory germ cell tumors : a phase II study. Ann Oncol 15 : 493-497, 2004

28） Oechsle K, et al : Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 60 : 850-855, 2011

29） Miki T, et al : Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 95 : 1879-1885, 2002